Shaw and Partners forecasts and 12 month TP have been revised (TP increases to $1.95 from $1.20). Our recommendation remains unchanged. BUY.
Respected Wall Street analyst Dr Raghuram Selvaraju has published a further research update on Cynata, reiterating the “BUY” recommendation and price target of $1.50
CYP has reported encouraging early safety and efficacy data in its Phase 1 trial of CYP-001 in GvHD. Shaw and Partners, forecasts, recommendation and 12 month TP ($1.20) remain unchanged. BUY.
Respected Wall Street analyst Dr Raghuram Selvaraju has published a research update on Cynata, reiterating the “buy” recommendation and price target of $1.50
Respected Wall Street analyst Dr Raghuram Selvaraju has published a research update on Cynata, reiterating the “buy” recommendation and price target of $1.50